Novel agents in mantle cell lymphoma

详细信息	查看全文 | 推荐本文 |

• 作者：Marcus S. Noel ; MD¹ ; ^{marcus_noel@urmc.rochester.edu} (Hematology/Oncology Fellow) ; Jonathan W. Friedberg ; MD² ; ^{jonathan_friedberg@urmc.rochester.edu} (Chief ; Hematology/Oncology Division ; Professor of Medicine ; Oncology) ; Paul M. Barr ; MD ; MMSc ; ^{paul_barr@urmc.rochester.edu} (Assistant Professor of Medicine ; Oncology)
• 关键词：mantle cell lymphoma ; novel agents ; B cell receptor
• 刊名：Best Practice Research Clinical Haematology
• 出版年：2012
• 期刊代码：36_15216926
• 类别：med
• 出版时间：June, 2012
• 卷：25
• 期：2
• 页码：191-200
• 文件大小：279 K

摘要

Mantle cell lymphoma is a mature B cell neoplasm constituting 5-7%of all non-Hodgkin lymphoma. Overall prognosis with current therapeutics remains poor, thus numerous novel agents are currently under investigation. In this review we focus on early phase trials that have demonstrated promise in mantle cell. Constitutive activation of signaling components downstream of the B cell receptor play an important role in the pathobiology of mantle cell lymphoma. Targeting of this signaling pathway has become a focus with specific agents under development including inhibitors of spleen tyrosine kinase, phosphoinositide 3-kinase and Bruton's tyrosine kinase. Promising data also supports further development of BH-3 mimetics, a crucial component of anti-apoptotic signaling. Histone deacetylase inhibitors have an established role in cutaneous T-cell lymphoma and are now under investigation in mantle cell lymphoma as well. With further understanding of cellular signaling, the armamentarium of treatment options will be enhanced, with the hope of improving the prognosis of this disease.